Business Context and Reporting Period
This Form 8-K is filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on August 8, 2017. The report announces the company's financial results for the second quarter of 2017. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were announced via a press release, which is attached as Exhibit 99.1 and incorporated by reference.
Material Changes
No material changes or comparative financial data are detailed within the body of this Form 8-K. The filing directs readers to the attached press release for the specific results and any changes versus the prior period.
Guidance, Outlook, and Risks
The filing contains no specific guidance, outlook, management commentary, or risk factors within the text provided. It explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting its legal liability status compared to a standard 10-K or 10-Q.
Investor Verification Checklist
- Verify the specific Q2 2017 financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 (Press Release).
- Confirm the company name is Zafgen, Inc., as the input metadata incorrectly listed Larimar Therapeutics, Inc.
- Review the press release for any updates on clinical trials or product development, as this is a biopharmaceutical company.
- Check subsequent filings for any restatements or updates to the Q2 2017 results.